Examine the evolution of Haemonetics' (HAE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

On May 21, 2026, Haemonetics Corp (HAE) shares rose 4.0%, bringing the current price to $61.94. The stock has fluctuated significantly over the past year, with

Investors need to pay close attention to GBTG stock based on the movements in the options market lately.

Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Haemonetics beats Q4 EPS and revenue estimates, shares rise 1.4%, but gross margin falls 120 basis points as the company sets its FY27 growth outlook.

Haemonetics NYSE: HAE reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies businesses offset continued pressure in Interventional Technologies.

Matson was the top performer as container shipping rates strengthened amid supply chain disruptions and management executed on operational efficiency initiatives. Revolve Group sold off as the online fashion retailer faced softer consumer demand and lower discretionary spending. We added to Haemonetics Corporation following recent share price volatility.

Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript

Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Haemonetics (HAE) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.24 per share a year ago.